Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

Taxes and Trump Have Stymied Starmer’s Growth Revival Pledge

View original at finance.yahoo.com
Taxes and Trump Have Stymied Starmer’s Growth Revival Pledge (Bloomberg) -- Weeks after his general election triumph, Keir Starmer sent voters a sobering message: “Things will get worse before we get better.” Most Read from Bloomberg Winners and Losers From Trump and Xi’s Beijing Summit Talks Hormuz Oil Flows Creep Hig…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Things will get worse before we get better

    60% confidence
  • Starmer vowed to boost UK GDP growth to the highest in the Group of Seven

    60% confidence
  • The economy has overtaken immigration as the top issue for UK voters

    60% confidence
  • The UK will be the worst affected G-7 economy, with growth predicted to almost halve in 2026

    60% confidence
  • UK policy decisions are probably pushing towards a slower pace of growth

    60% confidence
  • Many UK voters say they feel no better off than they did in 2024

    60% confidence
  • The underlying UK economic picture is one of an economy growing at a pretty soft pace

    60% confidence
  • UK unemployment is close to a post-pandemic high, inflation is accelerating, living standards have stalled, and growth is expected to slow to the weakest in three years

    60% confidence
  • UK GDP growth will almost halve in 2026 due to Iran War fallout

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com